Tag Archives: diabetes

New insights into adult-onset type 1 diabetes

Diabetes News

[ad_1]

This article has been reviewed according to Science X’s editorial process
and policies.
Editors have highlighted the following attributes while ensuring the content’s credibility:

fact-checked

peer-reviewed publication

trusted source

proofread


Credit: Pixabay/CC0 Public Domain

× close


Credit: Pixabay/CC0 Public Domain

Type 1 diabetes, a chronic condition affecting millions of young individuals globally, is not exclusive to childhood. As many as half of all cases are diagnosed during adulthood, and there is a need to understand the factors contributing to the development of type 1 diabetes in adults.

A new study at Karolinska Institutet now provides new insights into the development of the disease in adults. The results are presented in The Lancet Diabetes & Endocrinology.

The research, conducted at the Institute of Environmental Medicine, was based on data from more than 2.8 million individuals, and the aim was to compare the heritability of type 1 in adults and children. The findings indicate that having a first-degree relative with the condition significantly increases the risk of developing type 1 diabetes as an adult, and the risk is higher if the relative developed diabetes early. Overall, heritability is lower for type 1 diabetes in adults than children.

Yuxia Wei, Ph.D. student at the Institute of Environmental Medicine and first author, notes, “Our study provides new insights on the causes of type 1 diabetes in adults. The lower in adults suggests that environmental factors play a larger role for disease development in adults than children.”

The study underscores the need for further research to identify contributing to adult-onset type 1 diabetes. “Understanding these factors is crucial for developing targeted interventions to prevent the disease’s development,” says Sofia Carlsson, senior lecturer at the Institute of Environmental Medicine.

More information:
Yuxia Wei et al, Familial aggregation and heritability of childhood-onset and adult-onset type 1 diabetes: a Swedish register-based cohort study, The Lancet Diabetes & Endocrinology (2024). DOI: 10.1016/S2213-8587(24)00068-8

Journal information:
The Lancet Diabetes & Endocrinology


[ad_2]

Source link

Sugar Free Gujiya Recipes:Holi 2024: How to make Sugar-free Dates Gujiya for diabetes

Diabetes News

[ad_1]

​Ingredients required​

2 cups refined flour, 500 mawa, 50 gms semolina, 1/2 cup dates puree, 4 tbsp roasted almonds, 4 tbsp roasted cashews, 2 tbsp roasted chironji, 2 tbsp roasted coconut, 4 tbsp ghee, 2 cups ghee, 1 cup water, and 1 tsp cardamom powder.

[ad_2]

Source link

Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity

Diabetes News

[ad_1]

Fractyl Health, Inc.

Fractyl Health, Inc.

Data provides first demonstration of glucose lowering and weight loss potency from pancreas-produced native human GLP-1, highlighting the capacity of pancreatic GLP-1 to provide metabolic control.

The human GLP-1 transgene sequence used in RJVA-001 was administered to eight-week-old db/db mice with established disease and resulted in up to 50% blood sugar lowering and 11% weight loss vs vehicle at four weeks after a single administration, compared to 32% glucose lowering and 2% weight loss vs vehicle with chronic semaglutide.

These results with a native, short half-life human GLP-1 sequence to be used in RJVA-001 build upon earlier results with a prototype transgene GLP-1 analogue.

BURLINGTON, Mass., March 12, 2024 (GLOBE NEWSWIRE) — Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced promising new preclinical findings for the first clinical candidate in its Rejuva® pancreatic gene therapy platform. RJVA-001 is the Company’s first GLP-1 gene therapy candidate to emerge from the platform, setting the stage for a potentially transformative approach to treating metabolic diseases, including obesity and T2D.

“As we advance our Rejuva program through preclinical development, we now observe that a single-dose administration of a human GLP-1 transgene (as in RJVA-001) can achieve durable lowering of blood sugar and body weight compared to vehicle or chronic semaglutide administration in the well-validated db/db mouse model of diabetes,” said Dr. Timothy Kieffer, Fractyl Health Chief Scientific Officer. “With these data, we are one step closer to IND enablement for RJVA-001 as part of our broader preclinical development package.”

These results show that the human GLP-1 coding sequence of RJVA-001 demonstrates potency on both glucose lowering and weight loss in db/db mice, the standard rodent T2D efficacy model used for clinical development. The Company has reached alignment with European regulators on the use of this efficacy model to support the submission of a Clinical Trial Application (CTA) in Europe.

“While there are clear benefits of GLP-1 for weight loss, glucose control, and metabolic health in general, there remains a need for advances in care that can offer a major step forward in GLP-1 therapy,” said Dr. Harith Rajagopalan, CEO of Fractyl Health. “Our goal with RJVA-001 is to change the trajectory of both obesity and T2D with a single administration therapy that offers the potential for the durable remission of metabolic disease.”

Fractyl Health anticipates progressing RJVA-001 through IND-enabling toxicity studies in 2024 and initiating First-in-Human clinical studies in 2025.

About Fractyl Health
Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including T2D and obesity. Despite advances in treatment over the last 50 years, T2D and obesity continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. Fractyl Health is based in Burlington, MA. For more information, visit www.fractyl.com or www.twitter.com/FractylHealth.

About Rejuva
Fractyl Health’s Rejuva® platform focuses on developing next-generation adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of T2D and obesity. The Rejuva platform is in preclinical development and has not yet been evaluated by regulatory agencies for investigational or commercial use. Rejuva leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas. The program aims to transform the management of metabolic diseases by offering novel, disease-modifying therapies that address the underlying root causes of disease.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the Company’s limited operating history; the incurrence of significant net losses and the fact that the Company expects to continue to incur significant net losses for the foreseeable future; the Company’s need for substantial additional financing; the Company’s ability to continue as a going concern; the restrictive and financial covenants in the Company’s credit agreement; the lengthy and unpredictable regulatory approval process for the Company’s product candidates; uncertainty regarding its clinical studies; the fact that the Company’s product candidates may cause serious adverse events or undesirable side effects or have other properties that may cause it to suspend or discontinue clinical studies, delay or prevent regulatory development, prevent their regulatory approval, limit the commercial profile, or result in significant negative consequences; additional time may be required to develop and obtain regulatory approval or certification for the Company’s Rejuva gene therapy candidates; the Company’s reliance on third parties to conduct certain aspects of the Company’s preclinical studies and clinical studies; the Company’s reliance on third parties for the manufacture of the materials for its Rejuva gene therapy platform for preclinical studies and its ongoing clinical studies; changes in methods of the Company’s Rejuva gene therapy candidate manufacturing or formulation; and any contamination or interruption in the Company’s Rejuva gene therapy candidates’ manufacturing process, shortages of raw materials or failure of the Company’s suppliers of plasmids and viruses to deliver necessary components could result in delays in the Company’s Rejuva gene therapy candidates’ preclinical and clinical development or marketing schedules. These and other important factors discussed under the caption “Risk Factors” in the Company’s prospectus filed with the Securities and Exchange Commission (the “SEC”) on February 2, 2024, and its other filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, the Company disclaims any obligation to do so, even if subsequent events cause its views to change.

Contacts
Corporate Contact
Lisa Davidson, Chief Financial Officer
ir@fractyl.com, 781.902.8800

Media Contact
Beth Brett, Corporate Communications
Bbrett@fractyl.com, 720.656.6544

Investor Contact
Stephen Jasper
Gilmartin Group
stephen@gilmartinir.com, 619.949.3681



[ad_2]

Source link

Certain people with Type 2 diabetes can now donate a kidney. A Mayo Clinic nephrologist explains – Post Bulletin

Diabetes News

[ad_1]

ROCHESTER — A change in federal guidelines for living organ donation opens the door for people with well-controlled Type 2 diabetes to become kidney donors.

“I think this is a very significant shift in the eligibility criteria for living kidney donation in the U.S.,” said Dr. Naim Issa, a transplant nephrologist at Mayo Clinic in Rochester, the county’s second-largest living organ donor center. “In Europe, actually, diabetes was not completely (a) contraindication to donate a kidney.”

Before the Organ Procurement and Transplantation Network updated its policies in 2022, a potential living kidney donor would be disqualified if they were diagnosed with either Type 1 or Type 2 diabetes.

“Diabetes, especially if it’s poorly controlled, can lead to complications affecting our vital organs, especially the kidneys, the eyes, the heart,” Issa said. “And diabetes, in fact, is the leading cause of kidney disease in the U.S.”

But now, people with Type 2 diabetes could become kidney donors if they meet certain critera. (Type 1 diabetes is still excluded.)

Through Mayo Clinic, a potential kidney donor would be eligible if they don’t use insulin, are not overweight, don’t have a family history of kidney disease and go through a health assessment. Right now, those donors would also need to be at least 60 years old, Issa said.

“If you’re young with Type 2 diabetes … (you’ll) have another 20, 30 years to live, and we don’t know what will happen to their kidney function and to their vital organs,” Issa said.

Additionally, potential donors between the ages of 60 and 64 would need to not be on any medications for their diabetes. But, at age 65 and older, they can be taking up to two oral medications and still be eligible, according to the Mayo Clinic guidelines.

While Issa said he only expects a “handful” of living kidney donations per year from donors who meet the Type 2 diabetes critera, he said this type of donation can be helpful in certain situations, such as when a person wants to donate a kidney to their spouse.

naim-issa-14325870.png

Dr. Naim Issa, a transplant nephrologist at Mayo Clinic in Rochester.

Contributed / Mayo Clinic

“If a wife needs a kidney, they don’t have any potential donors, instead of staying on the waiting list for five to seven years,” Issa said, “Let’s say the husband is diabetic, but very well-controlled. (He’s) lean, maybe takes one medication, older than 65 and the diabetes did not affect any of the vital organs, the heart, the kidneys or the eyes.”

The expanded critera for living kidney donation comes at a time when, Issa said, the need for kidney transplants is increasing and the wait time for kidneys from deceased donors can last years for some patients.

“People are getting older, more diabetes and more obesity causing more and more kidney disease in this country — we have more than 90,000 people waiting for a kidney transplant,” Issa said. “This is mainly to address the increasing demand fo rkidneys and provide some people with a better chance for successful transplant and, of course, improve quality of life.”

Deceased donors with diabetes have been able to donate kidneys, Issa said, if their organs weren’t substantially harmed by their diabetes.



[ad_2]

Source link

Analysis of Hematological Parameters in Type 1 and Type 2 Diabetes Patients

Diabetes News

[ad_1]

The following is a summary of “Changes in selected hematological parameters in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis,” published in the February 2024 issue of Hematology by Bambo et al.


Researchers conducted a retrospective study to uncover pooled mean differences in white and red blood cell parameters among diabetic patients, aiming to shed light on potential hematological imbalances in type 1 and type 2 diabetes mellitus.

Using appropriate entry terms, they extensively searched articles in various bibliographic databases, including PubMed, Cochrane Library, Scopus, Web of Science, PsycINFO, Embase, online archives, and university repositories. Relevant studies were identified based on eligibility criteria. Data, including author details, study characteristics, diabetes type, sample size, and hematological parameter means with SD, were extracted in Excel and analyzed in Stata 11. Pooled standardized mean difference (SMD) was determined with a random effects model, assessing heterogeneity using Higgins’ I2 statistics. Egger’s test and funnel plot analysis evaluated bias. A sensitivity analysis assessed the impact of small studies.

The results showed 39,222 articles following methodology screening, 22 articles with 14,041 participants (6,146 T2DM, 416 T1DM patients, and 7,479 HCs). Pooled SMD in TLC were 0.66, 109 for T2DM and -0.21 for T1DM. Absolute differential WBC counts in T2DM showed differences of 0.84 (neutrophils), -1.59 (eosinophils), 3.20 (basophils), 0.36 (lymphocytes), and 0.26 (monocytes). Relative differential counts in T2DM were neutrophils (1.31%), eosinophils (-0.99%), basophils (0.34%), lymphocytes (-0.19%), and monocytes (-0.64%). In T1DM, SMD of WBC  109 parameters were neutrophils (-0.10), lymphocytes (-0.69), monocytes (0.19), and basophils (-0.32). Pooled SMD in RBC parameters for T2DM were: RBC (-0.57, 106/μL), Hb (-0.73 g/dL), and HCT (-1.22%). In T1DM, RBC, Hb, and HCT were -1.23 (106/μL), -0.80 g/dL, and -0.29%, respectively.

They concluded that T2DM showed elevated white & specific cell types, while T1DM had decreased white & red blood cell parameters, highlighting diabetes’ impact on blood composition.

Source: frontiersin.org/articles/10.3389/fmed.2024.1294290/full

[ad_2]

Source link

‘I’m a diabetes doctor – these five exercises could keep blood sugar levels in check’

Diabetes News

[ad_1]

Diabetes raises the spectre of dangerous complications posed by high levels of sugar in your blood.

Fortunately, lifestyle changes, including exercise, are some of the best weapons you can add to your arsenal of protection against dangerously high blood sugar levels.

Physical activity not only lowers your blood glucose levels, but it also boosts your body’s sensitivity to insulin, countering insulin resistance.

Insulin resistance occurs when your body’s cells don’t respond properly to insulin, leading to high blood sugar levels. However, exercise could make you more insulin sensitive, helping to manage high blood sugar levels more effectively.

Fortunately, a diabetes doctor has outlined the five best exercises for diabetics.

1.Walking

One of the most common exercises in the world, walking can be easily done anywhere you go.

An endocrine specialist, known on TikTok as The Voice of Diabetes, said: “What I recommend is about 30 minutes of brisk walking five times a week.”

2.Tai Chi

This Chinese martial arts practice is surprisingly good for lowering blood sugar levels, according to the diabetes specialist. She added: “It also helps your mental health. It helps people calm down. It involves a lot of slow different movements so Tai Chi is a great option.”

3.Yoga

This popular exercise has been proven to lower blood sugar levels, making a “great option” for diabetics.

4.Dancing

You might not associate dancing with exercise, but this fun physical movement could also benefit diabetics. The expert said: “Dancing is also good to lower blood sugar levels. And believe it or not, it actually helps your mental health.

“It can also reduce anxiety and depression. So I mean we could all benefit from some dancing.

5.Swimming

Swimming is another “wonderful option” for diabetics. The expert shared it can also stretch your muscles and joints.

The expert said: “It puts no strain on your joint muscles, so you don’t have to worry about knee replacement with swimming.”

[ad_2]

Source link

Diabetes risk is noticeable in young Samoan children

Diabetes News
Measuring Blood sugar

[ad_1]

Obesity is a serious problem worldwide, with over 4 million deaths yearly due to being overweight or obese. Even children are affected, with rates increasing dramatically since 1975. Nicola Hawley, from Yale, studies how obesity affects maternal and child health. She and her colleague, Courtney Choy, have been studying obesity in Samoa for almost ten years, focusing on child health in the Pacific.

A new study by Choy and Hawley revealed a significant rise in overweight or obese Samoan children, doubling from 16% to 36% between 2015 and 2020. In their latest research, published in Pediatric Obesity, they found alarming rates of diabetes and high blood pressure in children as young as 6 to 9 years old. About one in ten children showed signs of prediabetes. However, specific early growth patterns could predict these health issues, aiding clinicians in identifying children who may require intervention.

Choy, the study’s lead author, said, “Those worrisome levels in and of themselves motivate us to continue our work and better understand the state of obesity, diabetes, and hypertension in Samoa.”

Obesity is one part of malnutrition, with underweight and micronutrient deficiencies being the other, says WHO. Factors like imported, low-nutrient foods, and rising costs of local produce contribute to obesity in Samoa. Modernization has led to less active lifestyles and poorer diets.

Only a tiny percentage of women maintain a healthy weight in Samoa. Hawley and Choy’s study is the first to assess childhood heart and metabolic risks in a nation with high adult obesity rates. Their long-term study could help pinpoint the best times and methods for interventions against adult diseases.

The study began nine years ago with Samoa’s Ministry of Health, the Bureau of Statistics, and the Ministry of Women, Community, and Social Development. Choy, initially a YSPH student, recruited participants during her summer MPH internship with Samoa’s Ministry of Health. She continued the project with a Fulbright fellowship and later as a PhD at Brown University, funded by the NIH. An NIH K99 grant now supports Choy’s research. Her focus on Pacific health stems from her upbringing in Hawai’i.

Choy and Hawley, both at Yale, met early on. Hawley admires Choy’s determination and transition from student to independent investigator. They share a passion for improving health in Samoa.

Hawley and Choy’s study in Samoa examines how social and cultural factors affect children’s well-being. They aim to develop interventions by understanding what works best at different ages and how to prevent adult diseases.

After collecting data, Choy shares findings with village participants and engages children by involving them in the process. Next, they plan to gather participants’ input to address risk factors related to obesity, diabetes, and other health issues, ensuring children can achieve their aspirations.

Hawley and Choy’s study gives valuable insights into childhood well-being in Samoa. By understanding the social and cultural context, they aim to develop effective interventions to promote health and prevent diseases in children, thus enabling them to realize their dreams.

Journal reference:

  1. Avery A. Thompson, Rachel L. Duckham et al., Sex differences in the associations of physical activity and macronutrient intake with child body composition: A cross-sectional study of 3- to 7-year-olds in Samoa. Pediatric Obesity. DOI: 10.1111/ijpo.12603.

[ad_2]

Source link

Two-Step Screening Uncovers Heart Failure Risk in Diabetes

Diabetes News

[ad_1]

TOPLINE:

A two-step screening, using a risk score and biomarkers, can identify patients with diabetes at a higher risk for heart failure who will most likely benefit from preventive drugs.

METHODOLOGY:

  • Researchers compared screening methods and downstream risk for heart failure in 5 years, particularly those without atherosclerotic cardiovascular disease (ASCVD).
  • They pooled data from 4889 patients (age ≥ 40 years, about half women) with diabetes, no heart failure at baseline, and no signs of ASCVD. All patients had undergone screening to determine their heart failure risk level.
  • Researchers assessed the heart failure risk for patients without ASCVD with one-step screening strategies:
  • They next assessed a sequential two-step strategy, using the second test only for those deemed low risk by the first, with a combination of two tests (WATCH-DM/NT-proBNP, NT-proBNP/hs-cTn, or NT-proBNP/echocardiography), the second used for those deemed low-risk by the first test.
  • The primary outcome was incident heart failure during the 5-year follow-up. The researchers also assessed the cost-effectiveness of screening and subsequent treatment of high-risk patients with a sodium-glucose cotransporter 2 inhibitor.

TAKEAWAY:

  • Overall, 301 (6.2%) heart failure events occurred among participants without ASCVD.
  • Of the heart failure events, 53%-71% occurred among participants deemed high risk by a one-step screening strategy, but 75%-89% occurred among patients assessed as high risk in two steps.
  • The risk for incident heart failure was 3.0- to 3.6-fold higher in the high- vs low-risk group identified using a two-step screening approach.
  • Among the two-step strategies, the WATCH-DM score first, followed by selective NT-proBNP testing for patients deemed low risk by the first test, was the most efficient, with the fewest tests and lowest screening cost.

IN PRACTICE:

“Matching effective but expensive preventive therapies to the highest-risk individuals who are most likely to benefit would be an efficient and cost-effective strategy for heart failure prevention,” the authors wrote.

SOURCE:

The study led by Kershaw Patel of the Houston Methodist Academic Institute, Houston, Texas, was published online in Circulation.

LIMITATIONS:

The study findings may not be generalized, as the study included older adults with a high burden of comorbidities. This study may have missed some individuals with diabetes by defining it with fasting plasma glucose, which was consistently available across cohort studies, instead of with the limited A1c data. Moreover, the screening strategies used did not consider other important prognostic factors, such as diabetes duration and socioeconomic status.

DISCLOSURES:

Two authors declared receiving research support from the National Heart, Lung, and Blood Institute. Several authors disclosed financial relationships with multiple pharmaceutical device and medical publishing companies in the form of receiving personal fees; serving in various capacities such as consultants, members of advisory boards, steering committees, or executive committees; and other ties.

[ad_2]

Source link

Global Diabetes Therapeutics and Diagnostics Set to Hit $132.0 Billion in 2028- Insights from BCC Research

Diabetes News

[ad_1]

Latest Study Forecasts Global Diabetes Therapeutics and Diagnostics Market to Surge to $132 Billion by 2028, Growing at a 5.2% CAGR

BOSTON, Jan. 16, 2024 /PRNewswire/ — The global market for diabetes therapeutics and diagnostics is experiencing remarkable growth, poised to reach $132.0 billion by 2028. Fueled by increasing diabetes prevalence and technological advancements, this market is at the forefront of healthcare innovation. In this overview, we explore the key factors propelling its expansion, highlighting the intersection of research, pharmaceutical development, and diagnostic technologies shaping the landscape of diabetes management worldwide. Join us as we navigate the dynamic trends and impactful solutions driving the global markets for diabetes therapeutics and diagnostics.

“According to the latest research study, the demand for Global Markets for Diabetes Therapeutics and Diagnostics to increase from $102.2 billion in 2023 to reach $132.0 billion by 2028, at a compound annual growth rate (CAGR) of 5.2% from 2023 through 2028.”

This comprehensive report delves into the far-reaching implications of current trends within the diabetes therapeutics and diagnostics market, offering insights into the market’s size, growth trajectory, and its impact on both global and key national markets. A thorough exploration of pharmaceutical and medical industry players is provided, including profiles of industry leaders and updates on mergers and acquisitions. The report further includes a detailed discussion on competitive intelligence, innovative technologies, market dynamics, and regional opportunities. Notably, it furnishes five-year global sales forecasts for leading drug and device categories, complemented by country-level breakdowns. The analysis extends to major players’ recent developments and product portfolios, with a keen focus on patent analysis to highlight technological trends across the U.S., Europe, and Japan. The market analysis culminates in estimates of the compound annual growth rate (CAGR) for the diabetes therapeutics and diagnostics market. Geographically, the report segments the global market into North America, Europe, Asia-Pacific, and the Rest of the World, utilizing 2022 as the base year for market estimates, projecting through year-end 2028.

The Diabetes Delivery Devices segment has experienced exceptional growth, particularly fueled by technological advancements like implantable insulin delivery pumps and external insulin pumps. Notably, the integration of wireless technology and miniaturization in medical device components is anticipated to spur innovation in diabetes care devices, thereby propelling market growth throughout the forecast period. The adoption of cutting-edge technologies such as 3D printing, artificial intelligence, and big data analytics in device manufacturing is contributing to reduced operating costs and enhanced product quality. Within the Asia Pacific region, India stands out with the highest growth rate, propelled by supportive government policies, increased awareness about diabetes, and the presence of dedicated associations and societies for diabetes control and monitoring. This growth trajectory positions India as a key player in the region, potentially surpassing the pace observed in the U.S. and other nations in the Asia Pacific region.

Discover More: Dive into the Details of the Global Markets for Diabetes Therapeutics and Diagnostics Market’s Growth Trajectory and Future Prospects. Click Here to Learn More

Driving forces behind the global markets for diabetes therapeutics and diagnostics market’s insights growth comprises:

  1. Increasing incidence & prevalence of diabetes- The increasing incidence and prevalence of diabetes globally have become a significant public health concern. The World Health Organization (WHO) estimates that the number of people with diabetes has risen sharply over the past few decades, reaching an alarming prevalence. Factors such as sedentary lifestyles, unhealthy dietary habits, and rising obesity rates contribute to the surge in diabetes cases. The condition not only poses immediate health risks but also leads to long-term complications such as cardiovascular diseases, kidney failure, and blindness. The economic burden of diabetes on healthcare systems is substantial, emphasizing the urgent need for effective preventive measures, education, and accessible healthcare resources to address and manage this growing health crisis.
  2. Changing lifestyle habits- Changing lifestyle habits have emerged as a key factor influencing health outcomes worldwide. In recent decades, a shift towards sedentary routines, poor dietary choices, and increased stress levels has significantly impacted public health. Sedentary lifestyles, characterized by reduced physical activity, contribute to the rising incidence of health issues such as obesity, cardiovascular diseases, and diabetes. Unhealthy dietary habits, often marked by high consumption of processed foods and sugary beverages, further exacerbate these health concerns. The modern pace of life, with heightened work-related stress and irregular sleep patterns, also plays a role in compromising overall well-being. Recognizing the impact of lifestyle choices on health, there is a growing emphasis on promoting healthier habits through education, awareness campaigns, and policy interventions to foster positive changes in daily routines and improve long-term health outcomes.
  3. Growing geriatric population– The growing geriatric population represents a significant demographic shift with profound implications for healthcare systems worldwide. As advancements in healthcare contribute to increased life expectancy, the proportion of elderly individuals is on the rise. This aging demographic trend is associated with a higher prevalence of chronic conditions and age-related health issues, placing additional demands on healthcare infrastructure and resources. Conditions such as cardiovascular diseases, osteoporosis, and neurodegenerative disorders become more prevalent in older age groups, necessitating specialized and comprehensive healthcare services. Addressing the unique healthcare needs of the elderly, including preventive measures, specialized medical care, and social support systems, becomes crucial in ensuring a healthy and dignified aging process for this expanding segment of the population. The phenomenon of a growing geriatric population underscores the importance of proactive healthcare planning and strategies to meet the evolving needs of an aging society.
  4. Increase in prevalence of chronic diseases- The increase in the prevalence of chronic diseases represents a global health challenge, with far-reaching implications for individuals, healthcare systems, and economies. Chronic diseases, such as heart disease, diabetes, and respiratory conditions, have become more prevalent due to factors like aging populations, changing lifestyles, and environmental influences. These conditions often require long-term management and care, placing a substantial burden on healthcare resources. The rise in chronic diseases not only impacts the quality of life for affected individuals but also contributes significantly to healthcare costs. Prevention and early intervention strategies, along with lifestyle modifications, are crucial in mitigating the growing burden of chronic diseases. Addressing this trend requires a comprehensive and coordinated approach, involving public health initiatives, medical research, and innovative healthcare delivery models to promote healthier living and enhance the management of chronic conditions on a global scale.

Request a Copy of the Global Markets for Diabetes Therapeutics and Diagnostics

Report Synopsis        

Report Metrics

Details

Base year considered

2022

Forecast Period considered

2023-2028

Base year market size

$97.3 billion

Market Size Forecast

$132.0 billion

Growth Rate

CAGR of 5.2% for the forecast period of 2023-2028

Segment Covered

Product Group, End-User, and Region

Regions covered

North America, Europe, Asia-Pacific, and Rest of the World (RoW).

Countries covered

U.S., Canada, Mexico, France, Germany, U.K., Italy, Spain, China, India, and Japan

Key Market Drivers

•  Increasing incidence & prevalence of diabetes

•  Changing lifestyle habits

•  Growing geriatric population

•  Increase in prevalence of chronic diseases

The Rising Demand for Global Markets for Diabetes Therapeutics and Diagnostics:

The escalating demand for global markets in diabetes therapeutics and diagnostics is indicative of the increasing prevalence of diabetes and the imperative for advanced healthcare solutions. With the market projected to reach $132.0 billion by 2028, the surge is fueled by a combination of technological innovations, heightened awareness, and the continuous pursuit of more effective treatment and diagnostic options. The escalating demand is not only a testament to the growing burden of diabetes but also underscores the vital role of pharmaceutical advancements and diagnostic technologies in addressing this global health challenge. As countries grapple with rising diabetes rates, the demand for cutting-edge therapeutics and diagnostics is a driving force propelling this market’s growth, emphasizing the urgent need for comprehensive solutions to better manage and combat the diabetes epidemic on a worldwide scale.

Trends and Innovations:

The landscape of global markets for diabetes therapeutics and diagnostics is shaped by dynamic trends and ongoing innovations. Notably, the Diabetes Delivery Devices segment has witnessed remarkable growth, propelled by technological advancements like implantable insulin delivery pumps and external insulin pumps. The integration of wireless technology and miniaturization in medical device components is fostering innovation in diabetes care, while 3D printing, artificial intelligence, and big data analytics are driving manufacturing efficiency. Amidst these trends, India stands out in the Asia Pacific region with the highest growth rate, supported by government policies, heightened diabetes awareness, and dedicated associations. These trends underscore a transformative era in diabetes management, where technological advancements and strategic initiatives converge to address the evolving needs of patients and healthcare systems globally.

Challenges and Opportunities:

The global markets for diabetes therapeutics and diagnostics present a landscape of both challenges and opportunities. The increasing prevalence of diabetes poses a substantial challenge to healthcare systems globally, necessitating innovative and scalable solutions. Rising healthcare costs, coupled with the complexities of managing chronic conditions, contribute to the challenges faced by the industry. However, within these challenges lie significant opportunities for growth and improvement. Technological advancements offer the potential for more efficient and effective diabetes management, from innovative therapies to advanced diagnostic tools. Additionally, the growing awareness of diabetes and proactive government policies present opportunities for market expansion, especially in regions like India, where a higher growth rate is anticipated. Successfully navigating these challenges and leveraging the opportunities can lead to transformative breakthroughs in diabetes care, benefiting both patients and the broader healthcare ecosystem.

This report on the Global Markets for Diabetes Therapeutics and Diagnostics provides comprehensive insights and analysis, addressing the following key questions:

  1. What are the anticipated dimensions and expansion pace of the diabetes therapeutics and diagnostics market?

    The market is expected to witness an increase from $97.2 billion in 2022 to $132.0 billion by 2028, with a compound annual growth rate (CAGR) of 5.2% throughout the forecast period.

  2. What factors contribute to the growth of the diabetes therapeutics and diagnostics market? 

    The market is experiencing growth driven by the increasing incidence and prevalence of diabetes, advancements in technology related to diabetes treatment and diagnostics, and strategic initiatives undertaken by major players in developed nations.

  3. What divisions are included in the diabetes therapeutics and diagnostics market?

    The market is categorized based on product group, end-user, and region. 

  4. Which segment is projected to lead the market by the conclusion of 2028 in terms of product groups? 

    The Diabetes Therapeutics segment is anticipated to dominate the market by the end of 2028. 

  5. In the diabetes therapeutics and diagnostics market, which region commands the greatest market share?

    North America boasts the highest market share in this sector.

  6. Which companies or players are prominent in the diabetes therapeutics and diagnostics market? 

    Key players in the market encompass Novo Nordisk A/S, Lilly, Boehringer Ingelheim International GmbH, AstraZeneca, Abbott, Merck & Co., Inc., Sanofi, Dexcom, Inc., Medtronic, and others.

Some of the Key Market Players Are:

  • 77 ELEKTRONIKA KFT.
  • ABBOTT
  • ALTUCELL
  • ASCENSIA DIABETES CARE HOLDINGS AG.
  • ASTRAZENECA
  • B. BRAUN SE
  • BIOCON
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • DANAHER
  • DEXCOM INC.
  • EMBECTA CORP.
  • INSULET CORPORATION.
  • JOHNSON & JOHNSON SERVICES INC.
  • LIFESCAN IP HOLDINGS LLC
  • LILLY
  • MEDTRONIC
  • MENARINI GROUP (A. MENARINI DIAGNOSTICS S.R.L)
  • MERCK & CO. INC.
  • MERCK KGAA
  • NEXTCELL PHARMA AB
  • NIPRO
  • NOVA BIOMEDICAL
  • NOVARTIS AG
  • NOVO NORDISK A/S
  • ROCHE (F. HOFFMANN-LA ROCHE LTD)
  • SANOFI
  • TAKEDA PHARMACEUTICAL COMPANY LIMITED.
  • TANDEM DIABETES CARE INC.
  • TERUMO CORPORATION
  • YPSOMED AG

Browse More Related Reports: 

Global Markets for Stem Cells: The global market for stem cells is characterized by dynamic advancements in regenerative medicine, offering promising avenues for therapeutic applications. Stem cells, known for their unique ability to differentiate into various cell types, hold immense potential for treating a range of diseases and injuries. This burgeoning market involves diverse sectors such as stem cell-based therapies, research tools, and regenerative medicine applications. Major players in the industry include notable biotechnology and pharmaceutical companies, as well as academic and research institutions. As the field continues to evolve, the global markets for stem cells are poised for significant growth, fueled by ongoing research breakthroughs, clinical trials, and increasing awareness of the transformative potential of stem cell-based therapies. The intersection of scientific innovation, regulatory advancements, and expanding therapeutic possibilities underscores the key role of stem cells in shaping the future of medicine and healthcare.

DNA Vaccines: Technologies and Global Markets: The realm of DNA vaccines represents a cutting-edge frontier in the field of immunization, combining genetic engineering and vaccination technologies. This market is characterized by the development and utilization of vaccines that leverage the genetic material of pathogens to stimulate an immune response. As a promising alternative to traditional vaccines, DNA vaccines offer advantages such as rapid development, scalability, and potential broader applicability across various diseases. Key players in this market include biotechnology companies, pharmaceutical firms, and research institutions driving innovation in vaccine development. The global market for DNA vaccines is witnessing significant growth, propelled by advancements in biotechnology, increased understanding of genetic immunization, and the ongoing pursuit of effective and versatile vaccine solutions against infectious diseases and other health challenges. As research and development efforts continue, the market for DNA vaccines is poised to play a pivotal role in shaping the future of preventive medicine on a global scale.

Directly Purchase a copy of the report with BCC Research.

For further information or to make a purchase, please get in touch with [email protected].  

About BCC Research

BCC Research provides objective, unbiased measurement and assessment of market opportunities with detailed market research reports. Our experienced industry analysts’ goal is to help you make informed business decisions, free of noise and hype.

Contact Us

Corporate HQ: BCC Research LLC, 49 Walnut Park, Building 2, Wellesley, MA 02481, USA

Email: [email protected] 
Phone: +1 781-489-7301

For media inquiries, email [email protected] or visit our media page for access to our market research library.

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.

Logo: https://mma.prnewswire.com/media/2183242/BCC_Research_Logo.jpg

SOURCE BCC Research LLC

[ad_2]

Source link

1 2 3 11